TY - JOUR
T1 - SARS-CoV-2 vaccination induces mucosal antibody responses in previously infected individuals
AU - PARIS Study Group
AU - Sano, Kaori
AU - Bhavsar, Disha
AU - Singh, Gagandeep
AU - Floda, Daniel
AU - Srivastava, Komal
AU - Gleason, Charles
AU - Amoako, Angela A.
AU - Andre, Dalles
AU - Beach, Katherine F.
AU - Bermúdez-González, Maria C.
AU - Cai, Gianna
AU - Cognigni, Christian
AU - Kawabata, Hisaaki
AU - Kleiner, Giulio
AU - Lyttle, Neko
AU - Mendez, Wanni
AU - Mulder, Lubbertus C.F.
AU - Oostenink, Annika
AU - Raskin, Ariel
AU - Rooker, Aria
AU - Russo, Kayla T.
AU - Salimbangon, Ashley Beathrese T.
AU - Saksena, Miti
AU - Sominsky, Levy A.
AU - Tcheou, Johnstone
AU - Wajnberg, Ania
AU - Carreño, Juan Manuel
AU - Simon, Viviana
AU - Krammer, Florian
N1 - Funding Information:
We thank the PARIS study participants for their generous and continued support. We would like to thank Kizzmekia Corbett and Barney Graham at the NIH VRC for sharing the HCoV spike expression plasmids. This work (cohort establishment, sample collection) is part of the PARIS/SPARTA studies funded by the NIAID Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract 75N93019C00051 (F.K., V.S.). In addition, the assay development and immune analysis work was funded by the Serological Sciences Network (SeroNet) in part with Federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. 75N91019D00024, Task Order No. 75N91021F00001 (F.K., V.S.). K.S. is supported by the Japanese Society for the Promotion of Science (JSPS) Overseas Research Fellowship.
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - Immune responses at the respiratory mucosal interface are critical to prevent respiratory infections but it is unclear to what extent antigen specific mucosal secretory IgA (SIgA) antibodies are induced by mRNA vaccination in humans. Here we analyze paired serum and saliva samples from patients with and without prior coronavirus disease 2019 (COVID-19) at multiple time points pre and post severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccination. Our results suggest mucosal SIgA responses induced by mRNA vaccination are impacted by pre-existing immunity. Indeed, vaccination induced a minimal mucosal SIgA response in individuals without pre-exposure to SARS-CoV-2 while SIgA induction after vaccination was more efficient in patients with a history of COVID-19.
AB - Immune responses at the respiratory mucosal interface are critical to prevent respiratory infections but it is unclear to what extent antigen specific mucosal secretory IgA (SIgA) antibodies are induced by mRNA vaccination in humans. Here we analyze paired serum and saliva samples from patients with and without prior coronavirus disease 2019 (COVID-19) at multiple time points pre and post severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccination. Our results suggest mucosal SIgA responses induced by mRNA vaccination are impacted by pre-existing immunity. Indeed, vaccination induced a minimal mucosal SIgA response in individuals without pre-exposure to SARS-CoV-2 while SIgA induction after vaccination was more efficient in patients with a history of COVID-19.
UR - http://www.scopus.com/inward/record.url?scp=85137098664&partnerID=8YFLogxK
U2 - 10.1038/s41467-022-32389-8
DO - 10.1038/s41467-022-32389-8
M3 - Article
C2 - 36050304
AN - SCOPUS:85137098664
SN - 2041-1723
VL - 13
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 5135
ER -